Healthy Hair, Skin & Nails Blend
Recherche publiée et base de preuves
Biotin (vitamin B7) is an essential cofactor for five carboxylases, and frank biotin deficiency causes alopecia and dermatitis that resolve with repletion. In people without a deficiency, however, the evidence that supplemental biotin improves hair, skin or nail outcomes is weak: systematic and narrative reviews consistently find only a handful of small, biased or negative studies. High-dose biotin is also a recognised cause of clinically significant interference in streptavidin-biotin immunoassays, producing falsely raised or lowered results for thyroid, cardiac, hormone and other analytes. Other B vitamins have their own dermatological evidence base, with nicotinamide the best studied, showing benefit for keratinocyte-cancer chemoprevention in immunocompetent high-risk patients but no benefit in organ-transplant recipients.
- La biotine (vitamine B7) est un cofacteur essentiel pour cinq carboxylases.
- Les revues n'ont trouvé qu'une poignée d'études humaines petites, biaisées ou négatives.
- Aucun essai de haute qualité n'a montré de bénéfice chez les personnes au statut normal.
38 études · 20 depuis 2023 · plus récente 2026
- Études citées
- 38
- Publiées 2023+
- 20
- Article le plus récent
- 2026
- Dernière révision
- oct. 2026
Thèmes récurrents dans la littérature
- biotin deficiency versus supplementation in replete individuals
- biotin-streptavidin immunoassay interference
- keratin and carboxylase biochemistry
- telogen effluvium and androgenetic alopecia adjuncts
- nutraceutical supplement trial quality
- nicotinamide and keratinocyte cancer chemoprevention
- brittle nail syndrome
38 études publiées.
Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.
- 01Directive clinique2026
2026 ETA guideline on interference in immunoassay measurements used in assessment of thyroid function.
Campi I, et al. · Eur Thyroid J · European Thyroid Association clinical guideline on immunoassay interference in thyroid function testing
The guideline listed biotin among pharmaceutical causes of thyroid immunoassay interference and stated that interference must be excluded in discordant thyroid results before diagnosing resistance to thyroid hormone or TSH-secreting tumours.
Résultat de sécurité signalé. Biotin intake is a recognised cause of erroneous thyroid function immunoassay results.
- 02Revue systématique2026
Chemoprevention of keratinocyte carcinomas and actinic keratoses in adults who were immunocompetent: a systematic review.
Susanto A, et al. · Clin Exp Dermatol · systematic review of 11 RCTs (n=7,355) of chemoprevention in immunocompetent adults, Cochrane RoB 2
Nicotinamide reduced SCCs by 30% and actinic keratoses by 13-35% across two trials. Daily sunscreen reduced AKs and SCCs, topical 5-FU reduced superficial BCCs, and oral retinoids and DFMO lacked adequate efficacy or safety.
- 03Revue systématique2023
Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss: A Systematic Review.
Drake L, et al. · JAMA Dermatology · systematic review of MEDLINE, Embase and CINAHL from inception to 20 October 2021, restricted to individuals with hair loss and no known baseline nutritional deficiency; quality graded by Oxford CEBM criteria
The review found that the safety and effectiveness of nutritional supplements and dietary interventions for hair loss remain unclear in people without a documented baseline deficiency. It is the most widely cited systematic appraisal of the supplement category in dermatology.
- 04Clinique humaine2026
Changes in ultraviolet a radiation-induced thymidine dimers and erythema after oral nicotinamide or polypodium leucotomos extract in healthy volunteers: a randomized intraindividual trial.
Faisal A, et al. · Photochem Photobiol Sci · randomised intraindividual trial, n=50 healthy volunteers (skin phototypes I-III) assigned to oral nicotinamide or Polypodium leucotomos extract, each compared before and after 30 days; no placebo arm
Nicotinamide raised the UVA minimal erythema dose by 26% (p = 0.0008) but did not reduce UVA-induced thymidine dimers in skin biopsies or urine. Polypodium leucotomos produced the same 26% erythema change, and neither treatment was compared with placebo.
- 05Clinique humaine2026
Effectiveness, Tolerability, and Acceptance of a Food Supplement in the Management of Non-Illness-Related Hair Loss and Thinning.
Proksch E, Bartylla S · J Cosmet Dermatol · open-label multicentre intra-individual study, n=112 adults (93.8% female) with light diffuse hair loss, oral supplement containing millet extract, pantothenic acid, L-cystine and biotin, 12 weeks
Hair density and anagen proportion increased and hair loss declined by 59% from baseline at week 12, and the product was generally well tolerated. There was no placebo or comparator group, and the effect cannot be assigned to pantothenic acid or biotin rather than the other components.
- 06Clinique humaine2025
The Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study.
Patel MN, et al. · Cureus · randomised, double-blind, placebo-controlled trial, 105 enrolled and 97 completing, three arms (placebo; 1.25 mg plant-derived biotin; 1.25 mg biotin plus 21.75 mg silica), 90 days
Participants received placebo or one of two botanical biotin preparations for 90 days with clinical and instrumental assessment of hair, skin and nail parameters. The dose tested (1.25 mg) is far below the 5-10 mg commonly sold, and the study evaluated proprietary botanical extracts rather than synthetic biotin alone.
- 07Clinique humaine2025
The Clinical Evaluation of Serum WS Biotin, a Novel Encapsulated Form of D-Biotin With Improved Water Solubility, for Anti-Hair Shedding Applications. A Prospective Single-Arm, Nonrandomized, Pretest-Posttest Study.
Gonzalez Fernandez D, et al. · Health Science Reports · prospective single-arm, non-randomised, pretest-posttest study, n=22 volunteers with moderate to excessive hair shedding, topical application daily for 3 months
The authors stated explicitly that biotin has long been used as an oral supplement to promote hair growth and strength without solid evidence supporting the practice. Their own study was uncontrolled, topical rather than oral, and used modified pull test, modified hair wash test and phototrichogrammetry endpoints.
- 08Clinique humaine2025
Nicotinamide for Skin Cancer Chemoprevention.
Breglio KF, et al. · JAMA Dermatol · retrospective propensity-matched cohort, US Veterans Affairs records, 12,287 nicotinamide-exposed vs 21,479 unexposed patients with prior skin cancer
Nicotinamide exposure was associated with a 14% overall reduction in subsequent skin cancer risk, rising to 54% when started after a first skin cancer, with the largest reduction for cutaneous SCC. Among solid organ transplant recipients there was no overall significant reduction, although early use was associated with fewer cSCCs.
- 09Clinique humaine2025
Biotin or Pyridoxine Versus Combined Regimen in the Treatment of Onychoschizia.
Shemer A, et al. · J Drugs Dermatol · retrospective comparative study, n=61 patients with idiopathic fingernail onychoschizia, oral biotin, pyridoxine or both for 3 months, assessed after 6 to 9 months
Complete response occurred in 69.6% with combined biotin and pyridoxine versus 10% with biotin alone and 11.1% with pyridoxine alone (P < .001). No adverse events were recorded; the design was retrospective and non-randomised.
- 10Clinique humaine2025
Nicotinamide for secondary keratinocyte carcinoma prevention in solid organ transplant recipients.
Hwang JC, et al. · Arch Dermatol Res · single-centre retrospective before-after cohort, n=47 solid organ transplant recipients taking oral nicotinamide for at least one year
Keratinocyte carcinoma count fell from 224 in the year before to 121 in the year after starting nicotinamide (p = 0.0012), with significant falls in SCC and SCC in situ but not BCC, and in 31 patients with two-year data the count fell from 234 to 167. There was no control group, and 34 of 81 screened patients were excluded.
- 11Clinique humaine2024
Efficacy of 5% topical minoxidil versus 5 mg oral biotin versus topical minoxidil and oral biotin on hair growth in men: randomized, crossover, clinical trial.
Valentim FO, et al. · Anais Brasileiros de Dermatologia · randomised crossover clinical trial in men comparing 5% topical minoxidil, 5 mg oral biotin, and the two combined
This randomised crossover trial directly compared oral biotin against an established topical hair-growth agent. The indexed record is a research letter with no abstract in PubMed or Europe PMC, so effect estimates were not extractable from the bibliographic record and the full text would need to be consulted before quoting a result.
- 12Clinique humaine2023
Impact of Biotin Supplementation on Human Chorionic Gonadotropin Immunoassays Utilizing Biotin-Streptavidin Binding Methods in Urine.
Goodrum JM, et al. · Clinical Chemistry · study of biotin supplementation effects on urinary hCG immunoassays that use biotin-streptavidin binding
Biotin supplementation was shown to affect hCG immunoassays that rely on biotin-streptavidin capture in urine, extending the interference problem beyond serum-based endocrine testing.
Résultat de sécurité signalé. Biotin supplementation can distort urinary hCG immunoassay results.
- 13Clinique humaine2023
Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
Allen NC, et al. · The New England Journal of Medicine · phase 3 randomised trial, organ-transplant recipients with at least two keratinocyte cancers in the past 5 years, nicotinamide 500 mg or placebo twice daily for 12 months, dermatologist examination every 3 months
This phase 3 trial tested whether the benefit seen in immunocompetent patients extended to immunosuppressed transplant recipients. It is the key negative counterweight to enthusiasm for B-vitamin chemoprevention and shows that benefit in one population does not generalise.
- 14Clinique humaine2023
Oral Nicotinamide for Actinic Keratosis Prevention in Kidney Transplant Recipients: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial.
Zhang H, et al. · Transplant Proc · pilot double-blind randomised placebo-controlled trial, kidney transplant recipients with prior keratinocyte carcinoma randomised 10 to nicotinamide and 11 to placebo, oral nicotinamide, 12 months
Nicotinamide did not reduce actinic keratosis development compared with placebo at 12 months (P = .38). Gastrointestinal symptoms in the run-in phase led to a lower dose being used, and 40% of the nicotinamide arm withdrew versus none on placebo.
Résultat de sécurité signalé. Gastrointestinal symptoms during the run-in prompted dose reduction, and 40% of participants in the nicotinamide arm dropped out.
- 15Clinique humaine2022
Efficacy of intramuscular injections of biotin and dexpanthenol in the treatment of diffuse hair loss: A randomized, double-blind controlled study comparing two brands.
Samadi A, et al. · Dermatol Ther · randomised double-blind trial comparing two brands of intramuscular biotin plus dexpanthenol (no placebo arm), n=50 patients with diffuse hair loss (41 women, 9 men), 6-week course with follow-up 8 weeks after the last session
Hair fall count and total hair density improved from baseline in both brand groups one and eight weeks after the last session, and the brands differed only in the terminal/vellus hair ratio. There was no placebo or untreated comparison group, so the change cannot be separated from the natural course of diffuse hair loss.
- 16Clinique humaine2021
Evaluation of biophysical skin parameters and hair changes in patients with acne vulgaris treated with isotretinoin, and the effect of biotin use on these parameters.
Aksac SE, et al. · Int J Dermatol · controlled two-group study, 30 patients per group with acne vulgaris on isotretinoin, with or without added oral biotin, four months
In the biotin group the anagen hair ratio rose and the telogen ratio fell, and skin hydration did not decline significantly, whereas hydration fell in the isotretinoin-only group. The allocation method and blinding are not described in the abstract.
- 17Clinique humaine2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC, et al. · Lancet Neurol · randomised double-blind placebo-controlled phase 3 trial (SPI2), n=642 adults with progressive multiple sclerosis, high-dose pharmaceutical oral biotin (MD1003), placebo-controlled phase lasting 15-27 months
High-dose biotin did not significantly improve disability or walking speed (12% versus 9% of participants improved), and serious adverse events were similar (26% in each group). Despite mitigation strategies, biotin led to inaccurate results for laboratory tests using biotinylated antibodies; the dose tested is far above those sold for hair, skin and nails.
Résultat de sécurité signalé. Biotin caused inaccurate results in laboratory tests that use biotinylated antibodies despite mitigation strategies.
- 18Clinique humaine2019
Treatment of brittle nail with a hydroxypropyl chitosan-based lacquer, alone or in combination with oral biotin: A randomized, assessor-blinded trial.
Chiavetta A, et al. · Dermatol Ther · randomised assessor-blinded trial, n=50 adults with brittle nail syndrome, hydroxypropyl chitosan nail lacquer alone or combined with oral biotin, 4 months
Nail dystrophy scores fell in both groups (by 57% with the lacquer alone and 62% with lacquer plus biotin), and a reduction of at least 50% was reached by 53% versus 80% of participants (p = .05). Baseline scores were higher in the biotin group, and there was no biotin-only or placebo arm.
- 19Clinique humaine2018
Comparative evaluation between two nutritional supplements in the improvement of telogen effluvium.
Sant'Anna Addor FA, et al. · Clin Cosmet Investig Dermatol · randomised comparison of two oral nutritional supplements (no placebo arm) in adult women with telogen effluvium, 180 days; one contained biotin, B-complex vitamins and folic acid among other nutrients, the other calcium pantothenate and thiamine nitrate with cystine, yeast, keratin and aminobenzoic acid
Both groups improved on clinical ratings of hair loss, volume, density, shine and strength at 180 days, but only the biotin/B-complex/folic acid group improved on digital trichoscopy (11.09% versus 7.76%) and on shine and strength at 90 days. Participant numbers are not given in the abstract and there was no placebo group.
- 20Clinique humaine2017
Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults.
Li D, et al. · JAMA · prospective study of biotin ingestion in healthy adults with paired hormone and non-hormone assay measurement
This is the landmark human demonstration that ingesting biotin at supplement doses alters the measured performance of hormone and non-hormone immunoassays in otherwise healthy people. It converted a laboratory curiosity into a recognised clinical safety issue.
Résultat de sécurité signalé. Directly demonstrated assay distortion in healthy adults after biotin ingestion.
- 21Clinique humaine2015
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
Chen AC, et al. · The New England Journal of Medicine · phase 3 double-blind randomised controlled trial, n=386 participants with at least two non-melanoma skin cancers in the previous 5 years, nicotinamide 500 mg twice daily or placebo for 12 months, 18-month follow-up
The trial evaluated the number of new basal-cell and squamous-cell carcinomas over a 12-month intervention period in high-risk immunocompetent participants. It remains the landmark demonstration that a B vitamin can alter a hard dermatological endpoint at pharmacological dose in a selected population.
- 22Clinique humaine2014
A randomized, double-blind, placebo-controlled study of a novel pantothenic Acid-based dietary supplement in subjects with mild to moderate facial acne.
Yang M, et al. · Dermatol Ther (Heidelb) · randomised double-blind placebo-controlled trial, forty-eight adults with mild to moderate facial acne (41 evaluable), oral pantothenic acid-based dietary supplement, 12 weeks
Total facial lesion count fell more with the pantothenic acid-based supplement than with placebo at week 12 (P = 0.0197), as did inflammatory lesions and Dermatology Life Quality Index scores, and the product was reported as well tolerated. The other contents of the supplement are not given in the abstract and the trial was small.
- 23Clinique humaine2005
Effects of vitamin-B complex supplementation on periodontal wound healing.
Neiva RF, et al. · J Periodontol · randomised double-masked placebo-controlled trial, n=30 adults with chronic periodontitis after access flap surgery, oral vitamin B-complex (thiamine, riboflavin, niacinamide, calcium pantothenate, pyridoxine, biotin, cyanocobalamin and folate) for 30 days, 180-day follow-up
Clinical attachment level changes were more favourable with the B-complex than with placebo (P = 0.024), while probing depth reduction, bleeding on probing, gingival and plaque indices did not differ between groups. The outcome was periodontal wound healing, not skin, hair or nails.
- 24Clinique humaine2004
The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial.
Allan SJ, et al. · Br J Dermatol · randomised double-blind placebo-controlled crossover trial of oral inositol supplements versus lactose placebo in fifteen patients with psoriasis taking lithium, with a further 11 patients with psoriasis not taking lithium
Inositol supplements significantly improved Psoriasis Area and Severity Index scores in patients taking lithium, but no effect was detected in the 11 patients not taking lithium. The benefit was confined to lithium-associated psoriasis.
- 25Clinique humaine2003
The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903].
Mills E, et al. · BMC Clin Pharmacol · randomised placebo-controlled blinded trial, 51 female and 17 male healthy volunteers (mean age 27 years), single dose of over-the-counter immediate-release niacin or placebo
All 33 volunteers given niacin flushed versus 1 of 35 on placebo, and niacin also caused generalised pruritus (75% versus 0%), chills, cutaneous tingling and gastrointestinal upset. Six participants did not tolerate the adverse effects and 3 required medical attention.
Résultat de sécurité signalé. A single over-the-counter niacin dose caused flushing in every recipient and pruritus in 75%, and 3 participants required medical attention.
- 26Clinique humaine2002
Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12.
Tjioe M, et al. · Acta Derm Venereol · randomised controlled trial, n=27 patients with long-term stable vitiligo, narrowband UVB phototherapy alone or combined with folic acid and vitamin B12, one year
Repigmentation occurred in 92% (25/27) of patients, but maximum repigmentation rates did not differ between UVB alone and UVB plus folic acid and vitamin B12. Adding the vitamins did not improve the outcome of phototherapy.
- 27Clinique humaine2001· Polish (English abstract)
[Evaluation of vitamin B6 and calcium pantothenate effectiveness on hair growth from clinical and trichographic aspects for treatment of diffuse alopecia in women].
Brzezińska-Wcisło L · Wiad Lek · non-randomised comparative clinical study, n=46 women aged from puberty to 30 years with diffuse alopecia, oral calcium pantothenate for 4-5 months or intramuscular vitamin B6, assessed clinically and by trichogram
Calcium pantothenate did not show a clear positive effect on diffuse alopecia in women, whereas parenteral vitamin B6 was reported to improve hair condition and reduce hair loss in some women, especially telogen-type loss. Group sizes and statistics are not given in the abstract, and vitamin B6 is not an ingredient of this blend.
- 28Clinique humaine1989· German (English abstract)
[Treatment of brittle fingernails with biotin].
Floersheim GL · Z Hautkr · uncontrolled case series, n=71 patients with brittle fingernails given oral biotin, 45 evaluable, average treatment 5.5 months
Of 45 evaluable patients, 41 (91%) showed firmer and harder nails and improvement was questionable in 4 (9%). There was no control group and only 45 of the 71 treated patients could be evaluated.
- 29In vitro2026
In-vitro verification of tolerance limits for biotin interference of routine biochemistry and immunology assays.
Swallow K, et al. · Annals of Clinical Biochemistry · samples spiked to serum concentrations equivalent to 0.05-3600 mg/day exogenous biotin, tested across all relevant laboratory assays
Biotin interference was assessed against allowable measurement uncertainty across the full routine biochemistry and immunology repertoire, and the authors noted that not all manufacturers have issued warnings or reassurances about their assays. Interference can raise or lower a result depending on assay format.
Résultat de sécurité signalé. Exogenous biotin at supplement-level doses can bias routine laboratory results in either direction, and manufacturer warnings are inconsistent.
- 30Revue2026
Biotin Supplements for Hair and Nail Regrowth: A Caution for Oncologists.
Mager L, et al. · JCO Oncology Practice · clinical commentary directed at oncologists whose patients take biotin for post-chemotherapy hair and nail regrowth
The article cautions oncologists about biotin supplements taken for hair and nail regrowth, a population in whom assay interference has direct consequences for tumour-marker and hormone monitoring. The PubMed record carries no abstract.
Résultat de sécurité signalé. Biotin supplementation flagged as a hazard in oncology practice.
- 31Revue2026
Adjunctive approaches for androgenetic alopecia: A clinical review of nutritional, light-based, topical, and lifestyle interventions.
Podolsky AS, et al. · Journal of the American Academy of Dermatology · clinical review appraising nutritional supplements and nutraceuticals, light-based therapies, topicals and lifestyle interventions for androgenetic alopecia
Among reviewed adjunctive interventions some demonstrated modest benefit while many lacked adequate data, with persisting gaps including small sample sizes, heterogeneous methods and limited long-term follow-up.
- 32Revue2025
Biotin Supplementation-The Cause of Hypersensitivity and Significant Interference in Allergy Diagnostics.
Lis K, et al. · Nutrients · review of biotin exposure via supplements, cosmetics and medicines in relation to hypersensitivity and allergy testing
The authors found little evidence that oral or topical biotin is a significant sensitising agent and characterised true biotin allergy as very rare, while identifying biotin as a significant source of interference in allergy diagnostic assays.
Résultat de sécurité signalé. Biotin interferes with allergy diagnostic immunoassays; direct sensitisation appears rare.
- 33Revue2024
Biotin for Hair Loss: Teasing Out the Evidence.
Yelich A, et al. · The Journal of Clinical and Aesthetic Dermatology · PubMed literature review of oral biotin for hair growth or quality, excluding case reports and case series; three studies met inclusion criteria
The single highest-quality included study was double-blind and placebo-controlled and found no difference between biotin and placebo for hair growth. The other two studied specific populations (isotretinoin-treated patients and post-sleeve-gastrectomy women), were susceptible to multiple biases, and had no striking results favouring biotin.
- 34Revue2017
A Review of the Use of Biotin for Hair Loss.
Patel DP, Swink SM, Castelo-Soccio L · Skin Appendage Disorders · review of published reports of biotin use for hair and nail disorders
This is the reference review establishing that reported clinical benefit from biotin is confined to patients with an underlying biotin deficiency or a specific inherited or acquired cause, and that evidence for supplementation in otherwise healthy individuals is lacking.
- 35Rapport de cas2025
High-Dose Biotin Supplementation Exacerbates Chronic Migraine: A Case Report.
Sanosi AA, et al. · International Medical Case Reports Journal · single patient with 20-year history of controlled classic migraine
A patient developed daily severe headaches unresponsive to triptans after starting biotin 10,000 mcg daily, with multiple emergency visits and significant quality-of-life impact. The proposed mechanism was alteration of mitochondrial energy metabolism affecting neurotransmitter synthesis.
Résultat de sécurité signalé. Chronic migraine exacerbation temporally associated with high-dose (10 mg) biotin supplementation.
- 36Rapport de cas2018
Suspected Testosterone-Producing Tumor in a Patient Taking Biotin Supplements.
Stieglitz HM, et al. · J Endocr Soc · single case report, perimenopausal woman taking biotin supplements
Abnormal results for TSH, ACTH, prolactin, testosterone and cortisol led to a suspected testosterone-producing tumour and a scheduled surgical procedure before biotin interference was identified. Interference with the TSH assay persisted 2 weeks after biotin was stopped.
Résultat de sécurité signalé. Biotin-induced immunoassay interference produced falsely high and falsely low hormone results, leading to a suspected tumour, unnecessary referrals and a scheduled surgical procedure.
- 37Rapport de cas2018
A Case of Anaphylaxis to Intramuscular but Not to Oral Application of Thiamine (Vitamin B1).
Aurich S, et al. · Iran J Allergy Asthma Immunol · single case report, 78-year-old woman receiving intramuscular thiamine injections for polyneuropathy
She had anaphylaxis after the fourth intramuscular thiamine injection, with a positive skin prick test to thiamine hydrochloride. A placebo-controlled oral challenge with thiamine was tolerated, so the reaction was attributed to the parenteral route.
Résultat de sécurité signalé. Anaphylaxis after intramuscular thiamine injection.
- 38Rapport de cas2001
Life-threatening eosinophilic pleuropericardial effusion related to vitamins B5 and H.
Debourdeau PM, et al. · Ann Pharmacother · single case report, 76-year-old woman taking vitamins B5 and H (pantothenic acid and biotin) for two months
She developed life-threatening eosinophilic pleuropericarditis with pericardial tamponade and blood eosinophilia, and infectious, malignant and rheumatic causes were excluded. She recovered and the eosinophilia resolved after the vitamins were withdrawn.
Résultat de sécurité signalé. Life-threatening eosinophilic pleuropericardial effusion with tamponade, temporally associated with combined pantothenic acid and biotin use and resolving on withdrawal.
Ce que ces preuves n'établissent pas.
No adequately powered randomised placebo-controlled trial has shown that biotin supplementation improves hair, skin or nail outcomes in people with normal biotin status; the only high-quality placebo-controlled study identified in a 2024 review found no difference from placebo. Doses commonly sold (5-10 mg, roughly 150-300 times the adequate intake) have no established efficacy threshold and are well within the range that distorts streptavidin-biotin immunoassays. The multi-ingredient 'hair, skin and nails' complex format has not been tested as a formulation against placebo for any hard endpoint, and benefits shown for one B vitamin at pharmacological dose in a selected population (nicotinamide in high-risk immunocompetent patients) do not generalise, as the negative transplant-recipient trial demonstrates.
Questions courantes sur la recherche.
- Why B vitamins for hair, skin, and nail research?
Several B vitamins are cofactors in keratinocyte metabolism — biotin for carboxylase enzymes, pantothenic acid as the coenzyme A precursor, niacinamide as the NAD precursor. The review literature links deficiencies of these micronutrients to disordered hair and nail growth, which is the research context for the formulation.
- Is there strong evidence for supplementation without a deficiency?
The published reviews are candid on this point: documented improvement is concentrated in cases with an underlying deficiency or pathology, and evidence for benefit in replete subjects is limited. The cited literature is the best guide to where the evidence is solid and where it thins out.
- What does the research on biotin supplementation show?
Frank biotin deficiency causes alopecia and dermatitis that resolve with repletion, but the evidence for supplementation in people with normal biotin status is weak. A 2024 review of oral biotin for hair growth or quality found only three eligible studies, and the single highest-quality one, which was double-blind and placebo-controlled, found no difference between biotin and placebo. A 2023 systematic review restricted to individuals with hair loss and no known baseline nutritional deficiency concluded that the safety and effectiveness of nutritional supplements for that group remain unclear.
- Does high-dose biotin interfere with laboratory tests?
Yes, and this is a documented rather than theoretical problem. A 2017 prospective study in healthy adults demonstrated that ingesting biotin at supplement doses altered measured results across paired hormone and non-hormone immunoassays that rely on streptavidin-biotin capture. Later work extended the finding to urinary hCG immunoassays, and a 2026 assessment spanning the routine biochemistry and immunology repertoire found bias in either direction, with the authors noting that not all manufacturers have issued warnings.
Disponible dans notre catalogue
À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.